Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events

<i>Background</i><i>:</i> Although lenvatinib has become the standard therapy for hepatocellular carcinoma (HCC), the high incidence rate of adverse events (AEs) is an issue. This study aimed to clarify the AEs of lenvatinib and the therapeutic impact of five days-on/two days...

Full description

Bibliographic Details
Main Authors: Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Shusuke Okamura, Yu Noda, Naoki Kamachi, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Miwa Sakai, Taizo Yamaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
lenvatinib
hepatocellular carcinoma
weekends-off
adverse events
molecular targeted agents
Online Access:https://www.mdpi.com/2072-6694/12/4/1010

Internet

https://www.mdpi.com/2072-6694/12/4/1010

Similar Items